Targeting inflammation: Cohort study of the influence of methotrexate therapy on sideropenic anemia and reduction of inflammatory markers in rheumatoid arthritis patients

Background/Aim. Rheumatoid arthritis (RA) is a systemic autoimmune disease that can cause destructive joint disease and progressive disability. The diagnosis of RA is based on laboratory and clinical evidence, which includes the analysis of inflammatory markers, hematological, and biochemical parameters. Methods. Fifty patients diagnosed with RA without methotrexate (MTX) therapy and 50 patients with therapy (MTX, 7.5 mg/week; after three months prednisolone 10 mg/day) were included in this study. After six months of therapy, inflammatory biomarkers, hematological, and biochemical parameters were analyzed. Results. Inflammatory biomarkers: sedimentation rate (SE), C-reactive protein (CRP), and anti-cyclic citrullinated peptide (anti-CCP) are significantly lower in the group of patients on therapy compared to patients without MTX therapy. Significant differences were not found for the rheumatoid factor (RF). Significant differences were not found for hematological parameters between the compared groups. Analysis of serum biochemical parameters showed significant differences for aspartate aminotransferase (AST) and iron values. In patients without MTX therapy, the incidence of anemia was recorded in 68%, which is significantly higher than the incidence of 32% in patients with therapy. Conclusion. Prescribed therapy has shown effectiveness in the treatment of RA and reduction of the inflammatory process. The success of the treatment depends on the timely diagnosis of RA. Postponement of therapy and late-detected disease prolongs therapy treatment and often requires a combination of several drugs.